Real-World Feasibility of Fibrosis-4-Based Fibrosis Risk Stratification in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Contreras DA, Ibrahim A.

Open source

DOI
10.7759/cureus.110815
Published
2026-06-14
Container
Cureus
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7759/cureus.110815,
  title = {Real-World Feasibility of Fibrosis-4-Based Fibrosis Risk Stratification in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.},
  author = {Contreras DA and  Ibrahim A.},
  year = {2026},
  journal = {Cureus},
  doi = {10.7759/cureus.110815},
  url = {https://doi.org/10.7759/cureus.110815}
}

RIS

TY  - JOUR
TI  - Real-World Feasibility of Fibrosis-4-Based Fibrosis Risk Stratification in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
AU  - Contreras DA
AU  -  Ibrahim A.
PY  - 2026
JO  - Cureus
DO  - 10.7759/cureus.110815
UR  - https://doi.org/10.7759/cureus.110815
ER  - 

APA

DA, C., & A., I. (2026). Real-World Feasibility of Fibrosis-4-Based Fibrosis Risk Stratification in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.. Cureus. https://doi.org/10.7759/cureus.110815

Source records